183 related articles for article (PubMed ID: 12562403)
1. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies.
Sthoeger ZM; Dayan M; Tcherniack A; Green L; Toledo S; Segal R; Elkayam O; Mozes E
Clin Exp Immunol; 2003 Feb; 131(2):385-92. PubMed ID: 12562403
[TBL] [Abstract][Full Text] [Related]
2. Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.
Dayan M; Segal R; Sthoeger Z; Waisman A; Brosh N; Elkayam O; Eilat E; Fridkin M; Mozes E
J Clin Immunol; 2000 May; 20(3):187-94. PubMed ID: 10941826
[TBL] [Abstract][Full Text] [Related]
3. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.
Waisman A; Ruiz PJ; Israeli E; Eilat E; Könen-Waisman S; Zinger H; Dayan M; Mozes E
Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4620-5. PubMed ID: 9114040
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function.
Sela U; Mauermann N; Hershkoviz R; Zinger H; Dayan M; Cahalon L; Liu JP; Mozes E; Lider O
J Immunol; 2005 Dec; 175(11):7255-63. PubMed ID: 16301630
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion.
Sela U; Hershkoviz R; Cahalon L; Lider O; Mozes E
J Immunol; 2005 Jan; 174(1):302-9. PubMed ID: 15611253
[TBL] [Abstract][Full Text] [Related]
6. A peptide based on the CDR1 of a pathogenic anti-DNA antibody is more efficient than its analogs in inhibiting autoreactive T cells.
Eilat E; Fridkin M; Mozes E
Immunobiology; 2000 Nov; 202(4):383-93. PubMed ID: 11131154
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
Mauermann N; Sthoeger Z; Zinger H; Mozes E
Clin Exp Immunol; 2004 Sep; 137(3):513-20. PubMed ID: 15320900
[TBL] [Abstract][Full Text] [Related]
8. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T-cell epitope in (NZBXNZW)F1 lupus-prone mice.
Brosh N; Dayan M; Fridkin M; Mozes E
Immunol Lett; 2000 Apr; 72(1):61-8. PubMed ID: 10789683
[TBL] [Abstract][Full Text] [Related]
9. Treatment of induced murine SLE with a peptide based on the CDR3 of an anti-DNA antibody reverses the pattern of pathogenic cytokines.
Brosh N; Zinger H; Mozes E
Autoimmunity; 2002 May; 35(3):211-9. PubMed ID: 12389646
[TBL] [Abstract][Full Text] [Related]
10. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
[TBL] [Abstract][Full Text] [Related]
11. Alterations in B cell development, CDR-H3 repertoire and dsDNA-binding antibody production among C57BL/6 ΔD-iD mice congenic for the lupus susceptibility loci sle1, sle2 or sle3.
Khass M; Schelonka RL; Liu CR; Elgavish A; Morel L; Burrows PD; Schroeder HW
Autoimmunity; 2017 Feb; 50(1):42-51. PubMed ID: 28166678
[TBL] [Abstract][Full Text] [Related]
12. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.
Eilat E; Dayan M; Zinger H; Mozes E
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1148-53. PubMed ID: 11158609
[TBL] [Abstract][Full Text] [Related]
13. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
14. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.
Brosh N; Eilat E; Zinger H; Mozes E
Immunology; 2000 Feb; 99(2):257-65. PubMed ID: 10692045
[TBL] [Abstract][Full Text] [Related]
15. Common occurrence of an antiidiotypic antibody that recognizes T14+ anti-DNA antibodies in patients with systemic lupus erythematosus.
Lim PL; Ng LW; Leung DT; Wong KC; Song SY; Chui YL; Leung JC; Lai KN; Lui SF
Arthritis Rheum; 1996 Dec; 39(12):1980-9. PubMed ID: 8961902
[TBL] [Abstract][Full Text] [Related]
16. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.
Sharabi A; Dayan M; Zinger H; Mozes E
J Clin Immunol; 2010 Jan; 30(1):34-44. PubMed ID: 19756988
[TBL] [Abstract][Full Text] [Related]
17. A peptide based on the sequence of the CDR3 of a murine anti-DNA mAb is a better modulator of experimental SLE than its single amino acid-substituted analogs.
Brosh N; Zinger H; Fridkin M; Mozes E
Cell Immunol; 2000 Oct; 205(1):52-61. PubMed ID: 11078607
[TBL] [Abstract][Full Text] [Related]
18. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression.
Zinger H; Eilat E; Meshorer A; Mozes E
Int Immunol; 2003 Feb; 15(2):205-14. PubMed ID: 12578850
[TBL] [Abstract][Full Text] [Related]
19. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.
Luger D; Dayan M; Zinger H; Liu JP; Mozes E
J Clin Immunol; 2004 Nov; 24(6):579-90. PubMed ID: 15622442
[TBL] [Abstract][Full Text] [Related]
20. In vitro T-cell functions specific to an anti-DNA idiotype and serological markers in patients with systemic lupus erythematosus (SLE).
Mendlovic S; Shoenfeld Y; Bakimer R; Segal R; Dayan M; Mozes E
J Clin Immunol; 1988 May; 8(3):178-87. PubMed ID: 2455730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
